How Will the Market React to CymaBay Therapeutics Inc (CBAY) Stock Getting a Bullish Rating

Monday, June 05, 2023 12:45 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to CymaBay Therapeutics Inc (CBAY) Stock Getting a Bullish Rating

CymaBay Therapeutics Inc (CBAY) stock is up 9.37% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

CymaBay Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CBAY!

See Full CBAY Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CBAY Stock Today?

CymaBay Therapeutics Inc (CBAY) stock is trading at $9.57 as of 12:44 PM on Monday, Jun 5, a gain of $0.16, or 1.7% from the previous closing price of $9.41. The stock has traded between $9.33 and $9.62 so far today. Volume today is less active than usual. So far 329,502 shares have traded compared to average volume of 1,272,438 shares. To see InvestorsObserver's Sentiment Score for CymaBay Therapeutics Inc click here.

More About CymaBay Therapeutics Inc

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta. Click Here to get the full Stock Report for CymaBay Therapeutics Inc stock.